期刊
INTERNATIONAL JOURNAL OF NANOMEDICINE
卷 14, 期 -, 页码 8321-8344出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S218085
关键词
manganese oxide nanoparticles; MRI; multimodal imaging; contrast agent; tumor therapy
资金
- National Key R&D Program of China [2018YFC0910602]
- National Natural Science Foundation of China [11727813, 81627807, 91859109, 81571725, 81871397, 81701853, 81660505, 81530058]
- Fok Ying-Tong Education Foundation of China [161104]
- Program for the Young Top-notch Talent of Shaanxi Province
- Research Fund for Young Star of Science and Technology in Shaanxi Province [2018KJXX-018]
- Natural Science Basic Research Plan in Shaanxi Province of China [2018JM7072]
- Fundamental Research Funds for the Central Universities [JB181203]
Contrast agents (CAs) play a crucial role in high-quality magnetic resonance imaging (MRI) applications. At present, as a result of the Gd-based CAs which are associated with renal fibrosis as well as the inherent dark imaging characteristics of superparamagnetic iron oxide nanoparticles, Mn-based CAs which have a good biocompatibility and bright images are considered ideal for MRI. In addition, manganese oxide nanoparticles (MONs, such as MnO, MnO2, Mn3O4, and MnOx) have attracted attention as T1-weighted magnetic resonance CAs due to the short circulation time of Mn(II) ion chelate and the size-controlled circulation time of colloidal nanoparticles. In this review, recent advances in the use of MONs as MRI contrast agents for tumor detection and diagnosis are reported, as are the advances in in vivo toxicity, distribution and tumor microenvironment-responsive enhanced tumor chemotherapy and radiotherapy as well as photothermal and photodynamic therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据